{"title":"126 Prognostic gene signature reflecting CD8+ T cell enrichment in early-stage triple-negative breast cancer","authors":"Chang-Min Kim, Y. Yu, Jin-Young Park, K. Park","doi":"10.1136/jitc-2022-sitc2022.0126","DOIUrl":null,"url":null,"abstract":"Background Triple-negative breast cancer (TNBC) is the most challenging subtype of breast cancer, and its prognosis is poor compared to the other subtypes. 1 Immune cells have critical role in tumor rejection and prognosis of patient with TNBC. 2 In early TNBC, CD8+ T cells infiltration is positively associ-ated with response to neo-adjuvant chemotherapy and prognosis of patients. 3 Recently, combination of immune checkpoint inhibitor, pembrolizumab, with standard chemotherapy has been approved for the neo-adjuvant setting. 4 However, there are no valid prognostic biomarkers that reflect the CD8+ T cell enriched tumor in patients with early TNBC. To establish an elaborate therapeutic strategy for TNBC, identification of biomarkers that reflecting feature of CD8+ T cell enriched TNBC is needed. RNA conducted the gene expression of sam-ples Single performed signature","PeriodicalId":398566,"journal":{"name":"Regular and Young Investigator Award Abstracts","volume":"18 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Regular and Young Investigator Award Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/jitc-2022-sitc2022.0126","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background Triple-negative breast cancer (TNBC) is the most challenging subtype of breast cancer, and its prognosis is poor compared to the other subtypes. 1 Immune cells have critical role in tumor rejection and prognosis of patient with TNBC. 2 In early TNBC, CD8+ T cells infiltration is positively associ-ated with response to neo-adjuvant chemotherapy and prognosis of patients. 3 Recently, combination of immune checkpoint inhibitor, pembrolizumab, with standard chemotherapy has been approved for the neo-adjuvant setting. 4 However, there are no valid prognostic biomarkers that reflect the CD8+ T cell enriched tumor in patients with early TNBC. To establish an elaborate therapeutic strategy for TNBC, identification of biomarkers that reflecting feature of CD8+ T cell enriched TNBC is needed. RNA conducted the gene expression of sam-ples Single performed signature